Microenvironment and Immunology

ANGPTL4 Induction by Prostaglandin E_2 under Hypoxic Conditions Promotes Colorectal Cancer Progression

Sun-Hee Kim¹, Yun-Yong Park², Sang-Wook Kim³, Ju-Seog Lee², Dingzhi Wang¹, and Raymond N. DuBois¹,4

Abstract

Prostaglandin E_2 (PGE_2), the most abundant COX-2–derived prostaglandin found in colorectal cancer, promotes tumor cell proliferation and survival via multiple signaling pathways. However, the role of PGE_2 in tumor hypoxia is not well understood. Here, we show a synergistic effect of PGE_2 and hypoxia on enhancing angiopoietin-like protein 4 (ANGPTL4) expression and that elevation of ANGPTL4 promotes colorectal cancer growth. PGE_2 induces ANGPTL4 expression at both the mRNA and protein levels under hypoxic conditions. Moreover, hypoxia induces one of the PGE_2 receptors, namely EP1. Activation of EP1 enhances ANGPTL4 expression, whereas blockade of EP1 by an antagonist inhibits PGE_2 induction of ANGPTL4 under hypoxic conditions. Importantly, overexpression of ANGPTL4 promotes cell proliferation and tumor growth in vitro and in vivo. In addition, treatment with ANGPTL4 recombinant protein increases colorectal carcinoma cell proliferation through effects on STAT1 signaling. The MAP kinase and Src pathways mediate ANGPTL4-induced STAT1 expression and activation. These results are relevant to human disease because we found that the expression of ANGPTL4 and STAT1 are elevated in 50% of human colorectal cancers tested and there is a positive correlation between COX-2 and ANGPTL4 as well STAT1 expression in colorectal carcinomas. Collectively, these findings suggest that PGE_2 plays an important role in promoting cancer cell proliferation via ANGPTL4 under hypoxic conditions. Cancer Res; 71(22): 7010–20. ©2011 AACR

Introduction

Recent evidence confirms a reduction in risk for colorectal and other cancers in individuals who regularly take aspirin or other nonsteroidal anti-inflammatory drugs. These drugs are potent inhibitors of COX-1 and COX-2. Elevation of COX-2 was found in approximately 50% of colorectal adenomas and 85% of adenocarcinomas (1, 2) and is associated with worse survival among patients with colorectal cancer (3). COX-2 converts free arachidonic acid into prostanoids, including prostaglandins (PG) and thromboxanes (TX). Prostaglandin E_2 (PGE_2) is the most abundant prostaglandin found in colorectal cancer (4). An increasingly large body of evidence has shown that PGE_2 mediates the tumor-promoting effects of COX-2 in colorectal cancer (5). PGE_2 treatment dramatically increased both small- and large-intestinal adenoma burden in ApcMin/+ mice and significantly enhanced azoxymethane–induced colon tumor incidence and multiplicity (6, 7). PGE_2 promotes tumor growth by stimulating EP receptor signaling with subsequent enhancement of cellular proliferation, promotion of angiogenesis, inhibition of apoptosis, and stimulation of invasion/motility (8).

Hypoxia is one of the most common and critical factors identified thus far in the regulation of cancer progression and metastasis (9, 10). Adaptation of tumor cells to hypoxia is achieved largely by undergoing genetic changes that enable them to survive and become more malignant or invasive (11). Hypoxia induces COX-2 expression and PGE_2 levels via hypoxic-inducible factor (HIF)-1, a major transcription factor that regulates the hypoxic response, in colorectal carcinoma cells (12, 13). Increased levels of PGE_2 during hypoxia, in turn, potentiates HIF-1 transcriptional activity and promotes colorectal carcinoma cell growth and survival (12), suggesting that cross-talk exists between PGE_2 and hypoxia. However, the mechanism through which PGE_2 promotes colorectal cancer progression in the hypoxic tumor microenvironment is unclear. We postulated that PGE_2 might mediate a pivotal tumor cellular adaptive response to hypoxia with the implication for connecting tumor hypoxia to cancer progression.

Angiopoietin-like protein 4 (ANGPTL4) is a secretory protein that is cleaved into an N-terminal coiled-coil fragment (N-ANGPTL4) and a C-terminal fibrinogen-like domain (C-ANGPTL4) that modulates the disposition of circulating triglycerides (14). Although the role of ANGPTL4 in lipid metabolism has been well characterized, its role in cancer progression is poorly understood. Although recent studies suggest that ANGPTL4 is involved in cancer progression, the precise role of ANGPTL4 in angiogenesis and cancer progression is still debated. For example, ANGPTL4 has been reported
to have proangiogenic effects and antiangiogenic effects in different models (15–17). Moreover, ANGPTL4 mediates TGF-β–induced lung metastasis of breast cancer (18) but inhibits metastasis of melanoma cells (19). These conflicting data support the need of additional research to address the role of ANGPTL4 in cancer progression.

In this study, ANGPTL4 is identified as a novel focal point of the cross-talk between PGE2 and hypoxia signaling pathways in colorectal cancer cells. Our results show that PGE2 and hypoxia synergistically induce ANGPTL4 expression via EP1. Importantly, we show that the elevation of ANGPTL4 promotes tumor growth in vitro and in vivo. Moreover, we identified STAT1 as a new target of ANGPTL4 and found that inhibition of STAT1 attenuated ANGPTL4 induction of colorectal cancer cell proliferation. We further elucidated the ANGPTL4 signaling pathways in response to STAT1 expression and activation. The maximal induction of ANGPTL4 required both hypoxia and PGE2, indicating the complex nature of interactions within the tumor microenvironment that affect cancer signaling pathways.

Materials and Methods

Reagents

PGE2, 17-phenyl-trinor-PGE2, and SC-19220 were purchased from Cayman Chemical Company. U73122, BAPTA-AM, PD98059, SU6656, and diphenylene iodonium (DPI) were purchased from EMD Chemicals. ONO-AE3-208 was kindly provided by Ono Pharmaceutical Co. Full-length and C-terminal ANGPTL4 recombinant proteins were obtained from R&D Systems.

Cell culture and treatment

LS-174T, HT-29, and HCT-116 were purchased from the American Type Culture Collection. All cells were routinely maintained in McCoy’s 5A medium containing 10% FBS, 100 units/mL penicillin, and 100 μg/mL streptomycin in a 5% CO2 humidified incubator at 37°C. Cells were exposed to hypoxia by placing them in a mixed-gas incubator that was infused with an atmosphere consisting of 94% N2, 5% CO2, and 1% O2. Cells were treated with ANGPTL4, washed with PBS, and incubated with 4% paraformaldehyde for 30 minutes at room temperature, and cells were treated without or with ANGPTL4 in serum-free medium for 3 days. Cell viability was determined using Cell Proliferation Reagent WST-1 (Roche Applied Science).

Western blotting

Whole cell lysates were prepared for Western blot analyses using lysis buffer containing 20 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1% TX-100, 1 mmol/L EDTA, pH 8.0, and 1 mmol/L phenylmethylsulfonylfluoride. Samples were denatured in a SDS sample buffer. Total proteins were separated by loading 20 μg of total cell lysate on a denaturing 10% SDS-PAGE and transferred to a nitrocellulose membrane. Membranes were blocked with 5% nonfat dry milk in PBS containing 0.1% Triton X-100 and incubated with primary antibodies that recognize STAT1, Src, phospho-Src (Cell Signaling Technology), ANGPTL4 (R&D Systems), ERK, phospho-ERK (Santa Cruz Biotechnology), and Actin (Sigma-Aldrich). Secondary antibody conjugated to horseradish peroxidase (Vector Laboratories Inc.) was used at 1:2,000 to detect primary antibodies, and enzymatic signals were visualized by chemiluminescence.

Immunohistochemistry

Cells were treated with ANGPTL4, washed with PBS, and fixed with 4% paraformaldehyde for 30 minutes at room temperature, and subsequent blocking with PBS containing 1% bovine serum albumin and 0.1% TX-100 for 30 minutes at room temperature. The cells were incubated with STAT1 antibody (Cell Signaling Technology) for 2 hours at room temperature, followed by biotinylated secondary antibody (Vector Laboratories Inc.) for 1 hour, then Fluorescein streptavidin (Vector Laboratories Inc.) for 30 minutes, and then 4’,6-diamidino-2-phenylindole (DAPI; Invitrogen) for 5 minutes to visualize nuclei. Cells were examined under a fluorescence microscope (Nikon ECLIPSE TE300) to determine localization of STAT1.

Immunofluorescence

Paraffin-embedded specimens were treated with xylene and ethanol to remove the paraffin. The slides were immersed in a pressure cooker at 125°C for 5 minutes for antigen retrieval. Endogenous peroxidase activity was blocked by incubation in 3% hydrogen peroxide in methanol for 10 minutes. After blocking and washing with PBS, sections were incubated with primary antibodies for 1 hour, followed by biotinylated secondary antibody (Vector Laboratories Inc.) for 1 hour. Membranes were washed with PBS, incubated with streptavidin-horseradish peroxidase (PTAVID; Vector Laboratories Inc.) for 30 minutes, and then incubated with DAB solution for 30 minutes. The slides were counterstained with hematoxylin and mounted with mounting medium. The expression of STAT1, Src, phospho-Src, ANGPTL4, and TGF-β was evaluated with a fluorescence microscope (Nikon ECLIPSE TE300).
3% H$_2$O$_2$ containing PBS solution for 10 minutes. The slides were blocked with 5% normal goat serum and incubated with anti-STAT1 (Cell Signaling), HIF-1a (BD Biosciences), and ANGPTL4 (Adipobioscience) at 4°C overnight. After washing with PBS, the slides were incubated with Goat anti-Rabbit HRP (Vector Laboratories). After washing, the slides were developed with 3,3'-diaminobenzidine reagent (Vector Laboratories) followed by counterstaining with hematoxylin.

RNA interference
siGENOME SMARTpool siRNAs targeting STAT1 (M-003543-01-000) were purchased from Dharmacon, Inc. LS174T cells were transfected with 20 nmol/L of STAT1 siRNA or nontargeting siRNA using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's specifications. The efficacy of knockdown was confirmed by Western blot analysis.

Xenograft study
All mice were housed and treated in accordance with protocols approved by the Institutional Care and Use Committee at The University of Texas MD Anderson Cancer Center. LS-174T cells (5 x 10^5) were injected s.c. into the flanks of nude mice. The tumor size was measured starting from 13 to 28 days after injection. After the mice were euthanized using CO$_2$ asphyxiation, necropsies were performed by Western blot analysis. The tumor weight and size. There are 4 known PGE$_2$ receptors (EP1, EP2, EP3, and EP4) that are typical G protein-coupled receptors. Because recent reports showed that hypoxia induced EP1 expression in osteoblastic cells (23), we examined the effect of hypoxia on EP1 expression in colorectal cancer cells. Indeed, hypoxia specifically increased only EP1 expression and not other PGE$_2$ receptors in LS-174T cells (Fig. 2A). Because LS-174T cells express high levels of EP4, we examined which receptor mediates the effects of PGE$_2$ on upregulation of ANGPTL4 expression. Treatment of LS-174T cells with an EP1 antagonist, SC19220, blocked PGE$_2$-induced ANGPTL4 induction under hypoxic conditions, whereas an EP4 antagonist, ONO-AE3-208, had no effect on ANGPTL4 expression (Fig 2B). Consistent with these results, a selective EP1 agonist (17-PT PGE$_2$) has the same effects as PGE$_2$ on ANGPTL4 expression (Fig. 2C). Because EP1 is coupled to the Gq/PLC/Ca$_{2+}$ pathway (24), we tested whether inhibition of this pathway attenuates PGE$_2$ induction of ANGPTL4. Treatment of LS-174T cells with a PLC inhibitor (U73122) and a Ca$_{2+}$-chelating agent (BAPTA) partially suppressed PGE$_2$-induced ANGPTL4 expression under hypoxic conditions, respectively (Fig 2D). These results reveal that EP1 is induced by hypoxia and mediates PGE$_2$ induction of ANGPTL4.

EP1 mediates PGE$_2$-stimulated ANGPTL4 expression during hypoxia
To explore why PGE$_2$ induces ANGPTL4 expression only under hypoxic conditions but not under normoxic conditions, we first examined the effects of hypoxia on PGE$_2$ receptor levels. There are 4 known PGE$_2$ receptors (EP1, EP2, EP3, and EP4) that are typical G protein-coupled receptors. Because recent reports showed that hypoxia induced EP1 expression in osteoblastic cells (23), we examined the effect of hypoxia on EP1 expression in colorectal cancer cells. Indeed, hypoxia specifically increased only EP1 expression and not other PGE$_2$ receptors in LS-174T cells (Fig. 2A). Because LS-174T cells express high levels of EP4, we examined which receptor mediates the effects of PGE$_2$ on upregulation of ANGPTL4 expression. Treatment of LS-174T cells with an EP1 antagonist, SC19220, blocked PGE$_2$-induced ANGPTL4 induction under hypoxic conditions, whereas an EP4 antagonist, ONO-AE3-208, had no effect on ANGPTL4 expression (Fig 2B). Consistent with these results, a selective EP1 agonist (17-PT PGE$_2$) has the same effects as PGE$_2$ on ANGPTL4 expression (Fig. 2C). Because EP1 is coupled to the Gq/PLC/Ca$_{2+}$ pathway (24), we tested whether inhibition of this pathway attenuates PGE$_2$ induction of ANGPTL4. Treatment of LS-174T cells with a PLC inhibitor (U73122) and a Ca$_{2+}$-chelating agent (BAPTA) partially suppressed PGE$_2$-induced ANGPTL4 expression under hypoxic conditions, respectively (Fig 2D). These results reveal that EP1 is induced by hypoxia and mediates PGE$_2$ induction of ANGPTL4.

ANGPTL4 promotes tumor growth in vitro and in vivo
To determine the biologic role of ANGPTL4 in regulating cancer cell proliferation, LS-174T cells were treated with full-length recombinant ANGPTL4 (F-ANGPTL4) and C-ANGPTL4, respectively. Our results showed that C-ANGPTL4 more dramatically promoted LS-174T cell proliferation than F-ANGPTL4 (Fig. 3A, top). In addition, C-ANGPTL4 exhibited similar effects on regulating HCT-116 and HT-29 cell proliferation (Fig. 3A, bottom). In contrast, both F-ANGPTL4 and C-ANGPTL4 had no effects on regulating LS-174T cell apoptosis (data not shown). To confirm the proliferative effect of ANGPTL4, we established LS-174T cells that overexpressed ANGPTL4 (ANGPTL4/LS-174T) and control cells (GFP/LS-174T). C-ANGPTL4 (37 kDa) was easily detected in the...
conditioned medium of ANGPTL4/LS-174T cells (Fig. 3B, top). Because ANGPTL4 is proteolytically cleaved upon secretion from cells, F-ANGPTL4 was strongly detected in the cell lysate but not the conditioned medium (data not shown). Consistent with above results, overexpression of ANGPTL4 enhanced cell proliferation (Fig. 3B, bottom). These results are consistent with our observation that PGE2 increases cell proliferation under hypoxic conditions (Fig. 3C).

To validate our in vitro results in vivo, we injected ANGPTL4/LS-174T or GFP/LS-174T cells into the flanks of nude mice. The tumor size was measured starting from 13 to 28 days after injection. Tumor weight and C-ANGPTL4 levels were also measured after mice were euthanized. As expected, C-ANGPTL4 levels were higher in the tumor tissue of mice injected with cells expressing ANGPTL4 than in the controls (Fig. 3D, left). Moreover, cells expressing ANGPTL4 formed larger tumors than the control cells (Fig. 3D, middle and right), suggesting that elevation of ANGPTL4 promotes colorectal cancer growth. Taken together, these results suggest that ANGPTL4 accelerates colorectal cancer growth by enhancing cell proliferation.

STAT1 is important for ANGPTL4-mediated cell proliferation

Although several recent reports have shown the role of ANGPTL4 in cancer progression (15, 25, 26), little is known about how ANGPTL4 regulates cell proliferation and what downstream targets of ANGPTL4 are involved in regulating cell proliferation. The microarray analysis revealed that C-ANGPTL4 treatment increased IFN-related gene expression, such as STAT1, IFI35, IFI9, and IRF1. These genes were validated by qRT-PCR (data not shown). We further showed that C-ANGPTL4 treatment induced STAT1 expression at both the mRNA and protein levels as well as its nuclear localization (Fig. 4A, top and middle). Immunohistochemical staining further revealed that STAT1 expression was elevated in tumor tissue derived from mice implanted with ANGPTL4/LS-174 cells as compared with the GFP control (Fig. 4A, bottom). Because STAT1 is overexpressed in head and neck and lung cancer and has been reported to have a proliferative effect (27, 28), we examined the contribution of STAT1 to C-ANGPTL4-induced cell proliferation. Knockdown of STAT1 significantly suppressed C-ANGPTL4-induced cell proliferation (Fig. 4B). Because extracellular signal–regulated kinase (ERK) and Src are known to be the critical signaling molecules for cell proliferation or survival (29), we determined whether these pathways are involved in C-ANGPTL4 induction of STAT1 expression. As shown in Fig. 4C, PGE2 was able to enhance the phosphorylation of Src and ERK as well as STAT1 expression under hypoxic conditions. Moreover, C-ANGPTL4 treatment induced phosphorylation of Src and ERK in time-dependent manners (Fig. 4D, top), whereas pharmacologic inhibitors of Src (SU6656) and ERK (PD98059) blocked STAT1 expression stimulated by C-ANGPTL4, respectively (Fig. 4D, middle). Recently, ANGPTL4 has been reported to stimulate NADPH-oxidase–dependent production of O$_2^-$, which in turn triggers the Src and ERK pathway (30). Therefore, we examined whether ANGPTL4 regulated Src and ERK activation and STAT1 expression via upregulating O$_2^-$ production. Indeed, inhibition of O$_2^-$ production by an NADPH oxidase inhibitor

---

**Figure 1.** PGE$_2$ enhances ANGPTL4 expression under hypoxic conditions. A and B, LS-174T cells were treated with the indicated concentrations of PGE$_2$ and exposed to normoxia/hypoxia for 12 hours (mRNA) or 48 hours (protein) to determine the expression of ANGPTL4. ANGPTL4 mRNA (A) and protein (B) levels were determined by qRT-PCR and ELISA analysis, respectively. C, ELISA analysis was done in HT-29 (left) and HCT-116 (right) cells exposed to normoxia/hypoxia or dimethyl sulfoxide (DMSO)/1 µmol/L PGE$_2$ for 48 hours. *, $P < 0.05$; ***, $P < 0.001$.
inhibitor (DP1) suppressed ANGPTL4 stimulated the phosphorylation of Src and ERK and the expression of STAT1 (Fig. 4D, bottom). Collectively, these results indicate that STAT1 is a downstream target of C-ANGPTL4 for regulating cancer cell proliferation and that STAT1 induction is dependent on NADPH-oxidase-mediated production of O$_2^-$, Src, and MAP kinase pathways.

**ANGPTL4 and STAT1 are elevated in human colorectal cancer specimens**

Because increased levels of COX-2 and a downstream product, PGE$_2$, have been reported in most human colorectal cancers (1) and hypoxia is one of the key elements in the tumor microenvironment that promotes cancer development and progression (9, 10), we examined ANGPTL4 levels in human colorectal cancer and the correlation of ANGPTL4 with COX-2 and STAT1 in human colorectal cancer. ANGPTL4 mRNA levels were elevated in 16 of 30 cancer specimens as compared with those in adjacent normal mucosa (Fig. 5A). Moreover, ANGPTL4 expression in human colorectal cancer specimens correlates with COX-2 expression ($r = 0.2433$, $P = 0.0056$). In addition, high STAT1 expression was found in 17 of 30 tumor tissues and is also correlated with ANGPTL4 expression ($r = 0.6861$, $P < 0.0001$). To support these findings, we used a public microarray database to retrieve gene expression data of colorectal cancer patients. Patients in the Moffitt cohort ($N = 177$) were dichotomized according to expression level of ANGPTL4. The overall survival rate of patients with higher expression of ANGPTL4 was significantly worse than that of those with lower expression of ANGPTL4 (Fig. 5B). In addition, the expression of COX-2 positively correlated with the expression of ANGPTL4 ($r = 0.434$, $P < 0.0001$) and STAT1 ($r = 0.232$, $P = 0.001$) in the Moffitt cohort (Fig. 5C). Therefore, these results suggest that elevation of ANGPTL4 could be relevant to human colorectal cancer progression.
Hypoxia in the tumor microenvironment contributes to cancer progression and metastasis by activating adaptive programs that promote cancer cell proliferation, survival, and motility as well as tumor-associated angiogenesis. It has been reported that there is a cross-talk between the COX-2 pathway and signaling pathways affected by hypoxia. For example, hypoxia induces COX-2 expression in colorectal cancer cells and vascular endothelial cells (12, 31). Reciprocally, COX-2–derived PGE2 regulates HIF-1 expression and transcriptional activity in those cells (12, 32). Although a connection between COX-2 and hypoxia has been established, the precise mechanisms by which PGE2 and hypoxia synergistically promote cancer progression are largely unclear. In this study, we identify ANGPTL4 as a novel PGE2 downstream target under hypoxic conditions in colorectal cancer cells. We also found that hypoxia–induced EP1 mediates the effects of PGE2 on regulation of ANGPTL4. Elevation of ANGPTL4 promotes tumor growth in vitro and in vivo, suggesting that ANGPTL4 can act as a downstream effector of PGE2 for adaptation of cancer cells to hypoxia. Our results suggest that the COX-2-PGE2 pathway plays an important role in adapting cancer cells to the tumor microenvironment such as hypoxia that promotes cancer progression.

**PGE2 and Hypoxia Synergistically Induce ANGPTL4 Expression**

![Figure 3. ANGPTL4 increases tumor growth in vitro and in vivo.](image)

- **A.** LS-174T cells were treated with full-length (F–A) or C-terminal fragment (C–A) of recombinant ANGPTL4 protein for 3 days to determine cell proliferation (top). HCT-116 and HT-29 cells were exposed to 100 ng/mL C-ANGPTL4 for 3 days and cell proliferation was analyzed (bottom). B, LS-174T cells were stably transfected with GFP or ANGPTL4 constructs. C-ANGPTL4 expression was determined by Western blotting after the collection of conditioned medium (top). These cells were incubated in serum-free medium for 3 days and then cell proliferation was tested (bottom). C, 1 μmol/L of PGE2 was treated in LS-174T cells exposed to normoxia/hypoxia for 3 days and cell proliferation assay was done. D, LS-174T cell stably transfected with GFP or ANGPTL4 constructs were injected into the flanks of nude mice. The tumor size (middle) was measured from 13 to 26 days after injection, and tumor weight (right) was also measured and C-ANGPTL4 level (left) was detected after mice were euthanized.

*; P < 0.05; **; P < 0.01; ***; P < 0.001.
results are supported by the observation that hypoxia specifically increases EP1 expression in bone cells. Hypoxia-induced EP1 may play a role in bone remodeling and repair in regions of compromised or damaged bone, where O2 tension is low (23). Our data showed that only hypoxia-induced EP1 mediated PGE2 induction of ANGPTL4, although EP4 expression is high in both normoxic and hypoxic conditions (Fig. 2). This result explains why PGE2 only induced ANGPTL4 under hypoxic conditions but not under normoxic conditions. Moreover, our results from immunochemistry studies showed that ANGPTL4
is expressed in hypoxic regions of the tumors (Supplementary Fig. S1) although HIF-1α, an indicator of hypoxia, and ANGPTL4 did not exactly colocalize in same cells but overlapped in the same area because HIF-1α is a transcription factor and ANGPTL4 is a ligand to be secreted and diffused in the tumors. Collectively, these findings imply that tumor hypoxia enhances PGE2 signaling through upregulating EP1 receptor expression, which may allow for adaptation of cancer cells to the tumor microenvironment.

The synergistic effects of hypoxia and other factors such as insulin, platelet-derived growth factor, and TNF-α targeting genes has been reported in multiple types of cells, including cancer cells (37, 38). In contrast to PGE2, these factors also induce the expression of target genes under normoxic conditions. Our results show that PGE2 induced ANGPTL4 expression only under hypoxic conditions. Several studies have revealed that ANGPTL4 is transcriptionally regulated in response to intracellular or extracellular signals (18, 39). Because HIF mediates hypoxia upregulation of ANGPTL4 in different types of cells and PGE2 enhances HIF-1 transcriptional activity (12, 13, 20–22), it is possible that HIF-1 mediates the effect of PGE2 on induction of ANGPTL4. However, our results show that inhibition of HIF-1 did not affect PGE2 induction of ANGPTL4 (data not shown). On the basis of the observations that ANGPTL4 is one of the peroxisome proliferator-activated receptor (PPAR) target genes (40) with several putative peroxisome proliferator response consensus sequences on its promoter (41) and PGE2 transactivates PPARδ activity (7), we postulate that PPARδ is a potential transcription factor that could regulate PGE2-mediated ANGPTL4 expression under hypoxic conditions. Further investigation is needed to test this hypothesis.
The functions of ANGPTL4 have been well established in regulating lipid metabolism through the inhibition of lipoprotein lipase (LPL). N-ANGPTL4, which assembles into multimeric structures, is essential to inhibit the activity of LPL (39). However, C-ANGPTL4 exists as a monomer and its functional role in monomeric form is still unclear. In addition to the role of ANGPTL4 in lipid metabolism, several recent studies have linked F-ANGPTL4 to angiogenesis and cancer development (15, 25, 26). However, few studies have delineated the biologic function of C- or N-ANGPTL4 in cancer progression. Here, we show that C-ANGPTL4 induces colorectal cancer cell proliferation more effectively than F-ANGPTL4 (Fig. 3A). In addition, our results show for the first time that C-ANGPTL4 induced colorectal cancer proliferation through upregulation of STAT1. STAT1 has been reported to stimulate cell growth and is overexpressed in head and neck and lung cancer (27, 28). In addition, activation of STAT1 promotes cell survival in Wilms tumor (27). Moreover, radiation induces STAT1 expression through activation of epidermal growth factor receptor in breast cancer cells (42). STAT1 has been reported to regulate the oncogenic genes Fos and Egr1 in the absence of STAT3 (43). However, little information regarding the mechanism by which STAT1 regulates cell proliferation and oncogenesis is available. Because our microarray data showed that C-ANGPTL4 increased several oncogenic genes, including Fos and Egr1 (data not shown), the effect of C-ANGPTL4 on these oncogenic genes via STAT1 may contribute to cancer cell proliferation. Moreover, we identified novel C-ANGPTL4 downstream targets, Src and ERK, which are critical for C-ANGPTL4 induction of STAT1 expression (Fig. 4). It has been well established previously that the Src and ERK are responsible for cell proliferation. Therefore, the role of ANGPTL4 in cancer development is likely conferred by C-ANGPTL4 through activating the signaling pathways which regulate cell proliferation. Although C- and F-ANGPTL4 have a fibrinogen-like domain of angiopoietin that binds to angiopoietin receptor Tie1 and Tie2, C- and F-ANGPTL4 do not have any significant affinity for those receptors (44). A recent report shows that C-ANGPTL4 interacts with integrin β1 and β5 and produces O2− to regulate anoikis resistance of cancer cells (30). Therefore, confirmation of the C-ANGPTL4 receptor such as integrins will add to our understanding of how C-ANGPTL4 regulates cell proliferation as well as angiogenesis and metastasis.

It is generally accepted that hypoxia in the tumor microenvironment promotes chemoresistance (45). It has been reported that COX-2 overexpressing cancer cells are more resistant to doxorubicin and gefitinib (46, 47). Moreover, STAT1 has been shown to play a role in chemoresistance (48). A recent study has shown that the IFN-related gene signature including STAT1 and its target genes is associated with resistance to DNA damage across multiple cancer cell lines and can affect resistance to chemotherapy (48). In addition, radioresistant tumor cells expressed higher STAT1 levels than control cells (28). In accordance with these published results, we found for the first time that STAT1 was upregulated by ANGPTL4, and our preliminary data showed that ANGPTL4 treatment suppressed oxaliplatin-induced cell death in LS-147T cells (data not shown). Furthermore, the expression of COX-2, ANGPTL4, and STAT1 in human colorectal cancer specimens seems to be correlated (Fig. 5). On the basis of these observations, it is conceivable that ANGPTL4 may contribute to the hypoxia or COX-2–induced drug resistance and may offer a therapeutic option for colorectal cancer patients.

In conclusion, our studies reveal the molecular mechanism by which PGE2 signaling and hypoxia coordinate promote tumor growth. We found that PGE2 enhanced ANGPTL4 expression via EP1 receptor signaling that was enhanced by hypoxia. Moreover, we provide in vitro and in vivo evidence showing that elevation of ANGPTL4 promotes tumor growth. These results indicate that PGE2 plays an important role in promoting a cellular adaptive response to hypoxia for their growth via ANGPTL4. Knowledge about the role of PGE2 in tumor hypoxia may enhance our understanding of how cancer cells adapt to hypoxia for their growth. It has not escaped our attention that other genes are also more dramatically induced under hypoxic conditions following PGE2 treatment. This group of genes may reveal other important connections between inflammatory mediators and cancer progression in the tumor microenvironment.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Marivonne Rodriguez, Sung-Nam Cho, and Hong Wu for technical assistance.

Grant Support

This work was supported by NIH Grants RO1DK 62112 (R.N. DuBois), P01-CA-77839 (R.N. DuBois), and R37-DK47297 (R.N. DuBois). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 14, 2011; revised August 9, 2011; accepted August 26, 2011; published OnlineFirst September 21, 2011.

References


ANGPTL4 Induction by Prostaglandin E$_2$ under Hypoxic Conditions Promotes Colorectal Cancer Progression

Sun-Hee Kim, Yun-Yong Park, Sang-Wook Kim, et al.

Cancer Res 2011;71:7010-7020. Published OnlineFirst September 21, 2011.

Updated version
Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-11-1262

Supplementary Material
Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2011/11/07/0008-5472.CAN-11-1262.DC1

Cited articles
This article cites 48 articles, 21 of which you can access for free at: http://cancerres.aacrjournals.org/content/71/22/7010.full#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at: http://cancerres.aacrjournals.org/content/71/22/7010.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.